Sionna Therapeutics (NASDAQ:SION) Director Peter Thompson Sells 85,918 Shares

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 85,918 shares of the stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the transaction, the director directly owned 2,469,959 shares in the company, valued at approximately $110,802,360.74. This represents a 3.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Trading Up 2.1%

Shares of NASDAQ SION opened at $44.94 on Friday. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of -23.28 and a beta of 1.33. Sionna Therapeutics, Inc. has a twelve month low of $16.38 and a twelve month high of $48.44. The business has a 50 day simple moving average of $40.28 and a 200-day simple moving average of $39.54.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.08). As a group, equities analysts predict that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Institutional Investors Weigh In On Sionna Therapeutics

Hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. acquired a new position in shares of Sionna Therapeutics during the first quarter worth approximately $667,000. Woodline Partners LP acquired a new stake in Sionna Therapeutics in the 1st quarter valued at approximately $837,000. Geode Capital Management LLC raised its stake in Sionna Therapeutics by 113.4% during the 2nd quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock valued at $5,020,000 after acquiring an additional 153,712 shares in the last quarter. Rhumbline Advisers acquired a new position in Sionna Therapeutics during the 2nd quarter worth $307,000. Finally, New York State Common Retirement Fund acquired a new position in Sionna Therapeutics during the 2nd quarter worth $118,000.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on SION shares. Freedom Capital lowered shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 20th. BTIG Research reissued a “buy” rating and issued a $58.00 target price on shares of Sionna Therapeutics in a report on Wednesday, May 13th. Wedbush began coverage on Sionna Therapeutics in a research note on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 target price for the company. JonesTrading upped their target price on Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Finally, Wall Street Zen cut Sionna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Sionna Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $53.22.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.